Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

525 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models.
Tucker ER, Jiménez I, Chen L, Bellini A, Gorrini C, Calton E, Gao Q, Che H, Poon E, Jamin Y, Martins Da Costa B, Barker K, Shrestha S, Hutchinson JC, Dhariwal S, Goodman A, Del Nery E, Gestraud P, Bhalshankar J, Iddir Y, Saberi-Ansari E, Saint-Charles A, Geoerger B, Marques Da Costa ME, Pierre-Eugène C, Janoueix-Lerosey I, Decaudin D, Nemati F, Carcaboso AM, Surdez D, Delattre O, George SL, Chesler L, Tweddle DA, Schleiermacher G. Tucker ER, et al. Among authors: jimenez i. Clin Cancer Res. 2023 Apr 3;29(7):1317-1331. doi: 10.1158/1078-0432.CCR-22-2274. Clin Cancer Res. 2023. PMID: 36602782 Free PMC article.
Feasibility and clinical integration of molecular profiling for target identification in pediatric solid tumors.
Pincez T, Clément N, Lapouble E, Pierron G, Kamal M, Bieche I, Bernard V, Fréneaux P, Michon J, Orbach D, Aerts I, Pacquement H, Bourdeaut F, Jiménez I, Thébaud E, Oudot C, Vérité C, Taque S, Owens C, Doz F, Le Tourneau C, Delattre O, Schleiermacher G. Pincez T, et al. Among authors: jimenez i. Pediatr Blood Cancer. 2017 Jun;64(6). doi: 10.1002/pbc.26365. Epub 2016 Nov 29. Pediatr Blood Cancer. 2017. PMID: 27896933
Circulating tumor DNA analysis enables molecular characterization of pediatric renal tumors at diagnosis.
Jiménez I, Chicard M, Colmet-Daage L, Clément N, Danzon A, Lapouble E, Pierron G, Bohec M, Baulande S, Berrebi D, Fréneaux P, Coulomb A, Galmiche-Rolland L, Sarnacki S, Audry G, Philippe-Chomette P, Brisse HJ, Doz F, Michon J, Delattre O, Schleiermacher G. Jiménez I, et al. Int J Cancer. 2019 Jan 1;144(1):68-79. doi: 10.1002/ijc.31620. Epub 2018 Oct 26. Int J Cancer. 2019. PMID: 29923174
Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1).
Bellini A, Pötschger U, Bernard V, Lapouble E, Baulande S, Ambros PF, Auger N, Beiske K, Bernkopf M, Betts DR, Bhalshankar J, Bown N, de Preter K, Clément N, Combaret V, Font de Mora J, George SL, Jiménez I, Jeison M, Marques B, Martinsson T, Mazzocco K, Morini M, Mühlethaler-Mottet A, Noguera R, Pierron G, Rossing M, Taschner-Mandl S, Van Roy N, Vicha A, Chesler L, Balwierz W, Castel V, Elliott M, Kogner P, Laureys G, Luksch R, Malis J, Popovic-Beck M, Ash S, Delattre O, Valteau-Couanet D, Tweddle DA, Ladenstein R, Schleiermacher G. Bellini A, et al. Among authors: jimenez i. J Clin Oncol. 2021 Oct 20;39(30):3377-3390. doi: 10.1200/JCO.21.00086. Epub 2021 Jun 11. J Clin Oncol. 2021. PMID: 34115544 Free PMC article.
Phase 1 dose-escalation and pharmacokinetic study of regorafenib in paediatric patients with recurrent or refractory solid malignancies.
Geoerger B, Morland B, Jiménez I, Frappaz D, Pearson ADJ, Vassal G, Maeda P, Kincaide J, Mueller U, Schlief S, Teufel M, Ploeger BA, Cleton A, Agostinho AC, Marshall LV. Geoerger B, et al. Among authors: jimenez i. Eur J Cancer. 2021 Aug;153:142-152. doi: 10.1016/j.ejca.2021.05.023. Epub 2021 Jun 20. Eur J Cancer. 2021. PMID: 34157616 Free article. Clinical Trial.
Reversible transitions between noradrenergic and mesenchymal tumor identities define cell plasticity in neuroblastoma.
Thirant C, Peltier A, Durand S, Kramdi A, Louis-Brennetot C, Pierre-Eugène C, Gautier M, Costa A, Grelier A, Zaïdi S, Gruel N, Jimenez I, Lapouble E, Pierron G, Sitbon D, Brisse HJ, Gauthier A, Fréneaux P, Grossetête S, Baudrin LG, Raynal V, Baulande S, Bellini A, Bhalshankar J, Carcaboso AM, Geoerger B, Rohrer H, Surdez D, Boeva V, Schleiermacher G, Delattre O, Janoueix-Lerosey I. Thirant C, et al. Among authors: jimenez i. Nat Commun. 2023 May 4;14(1):2575. doi: 10.1038/s41467-023-38239-5. Nat Commun. 2023. PMID: 37142597 Free PMC article.
Prognostic factors of overall survival in children and adolescents enrolled in dose-finding trials in Europe: An Innovative Therapies for Children with Cancer study.
Carceller F, Bautista FJ, Jiménez I, Hladun-Álvaro R, Giraud C, Bergamaschi L, Dandapani M, Aerts I, Doz F, Frappaz D, Casanova M, Morland B, Hargrave DR, Marshall LV, Vassal G, Pearson AD, Geoerger B, Moreno L. Carceller F, et al. Among authors: jimenez i. Eur J Cancer. 2016 Nov;67:130-140. doi: 10.1016/j.ejca.2016.08.008. Epub 2016 Sep 21. Eur J Cancer. 2016. PMID: 27662616
Early phase clinical trials of anticancer agents in children and adolescents - an ITCC perspective.
Moreno L, Pearson ADJ, Paoletti X, Jimenez I, Geoerger B, Kearns PR, Zwaan CM, Doz F, Baruchel A, Vormoor J, Casanova M, Pfister SM, Morland B, Vassal G; Innovative Therapies for Children with Cancer (ITCC) Consortium. Moreno L, et al. Among authors: jimenez i. Nat Rev Clin Oncol. 2017 Aug;14(8):497-507. doi: 10.1038/nrclinonc.2017.59. Epub 2017 May 16. Nat Rev Clin Oncol. 2017. PMID: 28508875 Free article. Review.
525 results